Singapore Therapeutics Development Review (STDR) 2026 (Jul) supports Singapore public-sector researchers with drug discovery and therapeutic platform funding to advance first- or best-in-class therapies.
A*STAR’s 2020 Terms and Conditions and Guidelines are now marked as superseded with effect from 1 November 2026. Download links for the STDR July 2026 application materials have also been updated.
Biomanufacturing Technology and Partnership (BioTAP) FI supports Singapore public-sector researchers developing biomanufacturing processes and analytical capabilities for GMP readiness and industry adoption.
Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge – Phase II: Stage I supports teams and organizations developing RNA-targeting prototypes to enable precision therapies for human disease.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
Cancer Research UK's CDD supports the development of novel cancer agents from preclinical stages to early clinical trials with expert resources, not monetary funding.
Industry Discovery & Development Partnership Program supports companies developing therapeutics and devices through research and clinical trials to advance products that cure, treat, or prevent type 1 diabetes.